The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Biogen (I); Corcept Therapeutics; Genzyme (I); Invitae; Novartis (I); Teva (I)
Speakers' Bureau - Biogen (I); Genentech (I); Genzyme (I); Ipsen; Novartis (I); Teva (I)
Research Funding - BioNTech (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Helix BioPharma (Inst); Idera (Inst); Lilly (Inst); MabVax (Inst); Merck (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst); Samumed (Inst)
Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered every three weeks in patients with advanced refractory tumors: Efficacy in dose-escalation and expansion cohorts.
 
Marc Ryan Matrana
Consulting or Advisory Role - Strata Oncology
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Eisai; Genentech; Merck
 
Frank Tsai
No Relationships to Disclose
 
James M. Cleary
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Merck; Tesaro
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Roche
 
Suma Satti
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Genentech; Merck
 
Erkut Borazanci
No Relationships to Disclose
 
Jacob Estes
No Relationships to Disclose
 
Justin Moser
Consulting or Advisory Role - Caris Life Sciences
 
Khanh Tu Do
Consulting or Advisory Role - Jackson Laboratory for Genomic Medicine; QED Therapeutics; Seagen
Research Funding - Lilly (Inst)
 
Lingling Du
No Relationships to Disclose
 
Sunil Sharma
Stock and Other Ownership Interests - Bauerfeind; Beta Cat Pharmaceuticals; ConverGene; Elevar Therapeutics; HLB; Proteus Digital Health; Salarius Pharmaceuticals; Stingray Therapeutics
Honoraria - Array BioPharma; Bauerfeind; Dracen; Exelixis; Exelixis; Hengrui Therapeutics; Loxo; Tarveda Therapeutics
Consulting or Advisory Role - Bauerfeind; Dracen
Research Funding - AADi; Celgene; City of Hope; City of Hope; Hengrui Therapeutics; Honor Health; Honor Health; Inhibrx; Merck; Novartis; OncoMed; Plexxikon; Syndax; Tesaro; Toray Industries
Patents, Royalties, Other Intellectual Property - International PCT Application No. PCT/US20/13618 Title: BISPHOSPHONATE CONJUGATES AND USES THEREOF; Provisional Application No. 62/961,930. Title: PepSeq as a platform to identify synthetic molecular binding agents; Provisional application number: 62/818,037 Title: Trisubstituted Pyrazolo [1, 5-a] Pyrimidine Compounds and Methods of Use Thereof
Travel, Accommodations, Expenses - Bauerfeind; Dracen; Exelixis; Hengrui Therapeutics; Loxo; Tarveda Therapeutics
 
Vivek Khemka
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Research Funding - Caris Centers of Excellence (Inst); Caris Life Sciences (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Jiangsu Hengrui Medicine (Inst); OncoMed (Inst); Plexxikon (Inst); Tesaro (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Valentin Kolmakov
Employment - PAREXEL
 
Takumi Kawabe
Employment - CanBas
Patents, Royalties, Other Intellectual Property - CanBas
 
Geoffrey Shapiro
Consulting or Advisory Role - Almac Diagnostics; Angiex; Artios; Astex Pharmaceuticals; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; Daiichi Sankyo; Fusion Pharmaceuticals; G1 Therapeutics; Ipsen; Lilly; Merck Serono; Pfizer; Roche; Seagen; Sierra Oncology
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Esperas Pharma (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
Travel, Accommodations, Expenses - Bayer; Bicycle Therapeutics; G1 Therapeutics; Lilly; Pfizer; Sierra Oncology